DOP2022000218A - Anticuerpos anti-phf-tau y usos de estos - Google Patents

Anticuerpos anti-phf-tau y usos de estos

Info

Publication number
DOP2022000218A
DOP2022000218A DO2022000218A DO2022000218A DOP2022000218A DO P2022000218 A DOP2022000218 A DO P2022000218A DO 2022000218 A DO2022000218 A DO 2022000218A DO 2022000218 A DO2022000218 A DO 2022000218A DO P2022000218 A DOP2022000218 A DO P2022000218A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
phf
tau antibodies
tau
tauopathies
Prior art date
Application number
DO2022000218A
Other languages
English (en)
Inventor
Ganesan Rajkumar
Luo Jinquan
Mercken Marc
Singh Sanjaya
Venkataramani Sathyadevi
LA PORTE Sherry
Van Kolen Kristof
Nanjunda Rupesh
Jaiprasart Pharavee
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of DOP2022000218A publication Critical patent/DOP2022000218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)

Abstract

Se describen anticuerpos monoclonales anti-PHF-tau y fragmentos de unión al antígeno de estos. Además, se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir afecciones, tales como tauopatías.
DO2022000218A 2020-04-08 2022-10-07 Anticuerpos anti-phf-tau y usos de estos DOP2022000218A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US202063026387P 2020-05-18 2020-05-18
PCT/IB2021/052890 WO2021205359A1 (en) 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DOP2022000218A true DOP2022000218A (es) 2023-04-30

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000218A DOP2022000218A (es) 2020-04-08 2022-10-07 Anticuerpos anti-phf-tau y usos de estos

Country Status (18)

Country Link
US (1) US20230151083A1 (es)
EP (1) EP4132569A1 (es)
JP (1) JP2023521763A (es)
KR (1) KR20220166308A (es)
CN (1) CN115697393A (es)
AU (1) AU2021251486A1 (es)
BR (1) BR112022020410A2 (es)
CA (1) CA3179914A1 (es)
CL (1) CL2022002766A1 (es)
CO (1) CO2022015737A2 (es)
CR (1) CR20220505A (es)
DO (1) DOP2022000218A (es)
EC (1) ECSP22078815A (es)
IL (1) IL297231A (es)
MX (1) MX2022012628A (es)
PE (1) PE20230385A1 (es)
TW (1) TW202204402A (es)
WO (1) WO2021205359A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202345899A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(三)
TW202346355A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000543A1 (en) * 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها

Also Published As

Publication number Publication date
CA3179914A1 (en) 2021-10-14
ECSP22078815A (es) 2022-11-30
CL2022002766A1 (es) 2023-04-21
MX2022012628A (es) 2023-01-11
BR112022020410A2 (pt) 2023-01-03
CR20220505A (es) 2023-05-31
CN115697393A (zh) 2023-02-03
PE20230385A1 (es) 2023-03-06
CO2022015737A2 (es) 2023-02-27
TW202204402A (zh) 2022-02-01
US20230151083A1 (en) 2023-05-18
JP2023521763A (ja) 2023-05-25
KR20220166308A (ko) 2022-12-16
IL297231A (en) 2022-12-01
AU2021251486A1 (en) 2022-12-08
WO2021205359A1 (en) 2021-10-14
EP4132569A1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
DOP2022000218A (es) Anticuerpos anti-phf-tau y usos de estos
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
AR053608A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
UY39699A (es) Anticuerpos anti-tau y usos de estos
CO2018012513A2 (es) Anticuerpos
CO2018010827A2 (es) Anticuerpos anti-factor bb del complemento y usos de estos
CL2022001769A1 (es) Anticuerpos anti-cd73 y usos de estos.
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
EA202190807A1 (ru) Антитела к синуклеину
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
CO2023013500A2 (es) Anticuerpos anti-cd19 y estructuras car-t
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
EA202092122A1 (ru) Антитела против tip-1 и их применения
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
BR112022020716A2 (pt) Anticorpos anti-tumor associados ao antígeno e usos dos mesmos
UY39698A (es) Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos
EA202092840A1 (ru) Антитела к cd33, биспецифические антитела к cd33/cd3 и их применение
AR115424A1 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33 / anti-cd3 y usos de estos
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
AR122715A1 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
CO2023010721A2 (es) Anticuerpos contra la calicreína plasmática y usos de estos
CL2023002213A1 (es) Anticuerpos contra la calicreína plasmática y usos de estos.